FDA 483 - American Red Cross Blood Services Heart of America Region - August 18, 2010

This FDA Form 483 document outlines observations made during an inspection of a facility involved in the collection and distribution of blood and blood components for homologous transfusion.

The inspection revealed several deficiencies:

1. **Distribution and Receipt Procedures:** The facility's procedures for distribution and receipt lacked a system to readily determine the distribution or receipt of each unit, which is critical for facilitating product recalls. This indicates a potential inability to effectively track products in the event of a recall.

2. **Standard Operating Procedures (SOPs):** Written SOPs detailing all steps for the collection and distribution of blood and blood components were not consistently maintained and followed. This suggests a lack of adherence to established protocols, potentially impacting product quality and safety.

3. **Adverse Reaction Investigations:** The facility failed to conduct thorough investigations of each reported adverse reaction. This is a critical deficiency as it prevents proper identification of root causes, implementation of corrective actions, and continuous improvement in patient safety.

4. **Personnel Adequacy:** The number of personnel responsible for the collection of blood or blood components was deemed inadequate. This inadequacy raises concerns about the competent performance of assigned functions and the assurance of the final product's safety, purity, potency, identity, and effectiveness.

These observations highlight significant issues within the facility's quality system, particularly concerning traceability, procedural adherence, adverse event management, and staffing levels, all of which have direct implications for the safety and quality of the blood